

Bahar ArtÄ±m Esen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104986/publications.pdf>

Version: 2024-02-01

56
papers

453
citations

840119

11
h-index

713013

21
g-index

56
all docs

56
docs citations

56
times ranked

859
citing authors

#	ARTICLE	IF	CITATIONS
1	Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center. <i>Journal of Rheumatology</i> , 2014, 41, 1304-1310.	1.0	75
2	The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 14.	2.1	61
3	Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. <i>Rheumatology International</i> , 2012, 32, 79-83.	1.5	58
4	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. <i>Lupus</i> , 2016, 25, 177-184.	0.8	47
5	Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. <i>Journal of Rheumatology</i> , 2017, 44, 619-625.	1.0	41
6	Femoral vein wall thickness measurement: A new diagnostic tool for Behçet's disease. <i>Rheumatology</i> , 2021, 60, 288-296.	0.9	27
7	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015, 17, 47.	1.6	16
8	Genetic screening of early-onset patients with systemic lupus erythematosus by a targeted next-generation sequencing gene panel. <i>Lupus</i> , 2022, 31, 330-337.	0.8	14
9	Capillaroscopic findings and vascular biomarkers in systemic sclerosis: Association of low CD40L levels with late scleroderma pattern. <i>Microvascular Research</i> , 2016, 108, 17-21.	1.1	13
10	Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. <i>Lupus</i> , 2018, 27, 1509-1516.	0.8	13
11	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	2.2	11
12	Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 379-388.	0.8	11
13	Clinical course of abdominal aortic aneurysms in Behçet disease: a retrospective analysis. <i>Rheumatology International</i> , 2019, 39, 1061-1067.	1.5	9
14	Autoimmune haemolytic anaemia and thrombocytopenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival. <i>Lupus</i> , 2019, 28, 1480-1487.	0.8	8
15	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. <i>Clinical Rheumatology</i> , 2016, 35, 2495-2499.	1.0	7
16	Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 466-474.	1.0	6
17	Description of damage in different clusters of patients with antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 433-442.	0.8	5
18	Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course. <i>Lupus</i> , 2021, 30, 1603-1608.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Favourable pregnancy outcome in Takayasu arteritis: a single-centre experience. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-7-10.	0.4	4
20	POS1257â€¦HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 912-913.	0.5	3
21	A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 2243-2247.	0.4	3
22	Domain I of Î²2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. <i>Lupus</i> , 2019, 28, 893-897.	0.8	2
23	Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. <i>Rheumatology International</i> , 2021, 41, 439-448.	1.5	2
24	A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. <i>Rheumatology International</i> , 2021, 41, 1667-1672.	1.5	2
25	Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 257-259.	0.7	2
26	The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 110-114.	0.4	2
27	A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis. <i>Open Access Rheumatology: Research and Reviews</i> , 2022, Volume 14, 39-42.	0.8	2
28	Biologics use in sle in 23 centers â€œ data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A9.1-A9.	0.5	1
29	High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e110-e110.	0.5	1
30	AB0766â€¦SUCCESSFUL TREATMENT OF ANKYLOSING SPONDILITIS ASSOCIATED AA AMYLOIDOSIS WITH SECUKINUMAB: A CASE SERIES WITH THREE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1409.3-1410.	0.5	1
31	FRI0473â€¦ASSESSMENT OF FEMORAL VEIN WALL THICKNESS WITH DOPPLER US AS A DIAGNOSTIC TOOL FOR BEHCETâ€™S DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 833.2-834.	0.5	1
32	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 555-564.	0.8	1
33	SAT0295â€¦Autoimmune Hemolytic Anemia and Thrombocytopenia in A Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey: Clinical Associations and Effect on Disease Damage and Survival. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 775.1-775.	0.5	0
34	O22â€œBoth Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (Î²2GPI) are capable of inhibiting IgA APS antibody binding. <i>Rheumatology</i> , 2019, 58, .	0.9	0
35	AB0524â€¦SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE FOLLOW-UP STUDY. , 2019, , .		0
36	P26â€¦Serum BAFF and APRIL as candidate biomarkers in systemic lupus erythematosus (SLE): a prospective follow-up study. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
37	P181â€¦Comparison of SLEDAI-2K and SLEDAI-2KG (glucocorticoid) indexes in patients with systemic lupus erythematosus (SLE). , 2020, , .		0
38	POS0142â€¦MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ASSOCIATED FACTORS: REAL LIFE DATA FROM A SINGLE CENTER. Annals of the Rheumatic Diseases, 2021, 80, 282.3-283.	0.5	0
39	AB0448â€¦SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: PREDOMINANCE OF PULMONARY FIBROSIS AS A RISK FACTOR FOR MORTALITY IN A SINGLE CENTER COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1251.2-1252.	0.5	0
40	POS1339â€¦MORE FREQUENT AND EARLIER HIP INVOLVEMENT IN SPONDYLOARTHRITIS ASSOCIATED WITH FAMILIAL MEDITERRANEAN FEVER. Annals of the Rheumatic Diseases, 2021, 80, 951.3-952.	0.5	0
41	POS1445â€¦RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS. Annals of the Rheumatic Diseases, 2021, 80, 1006.2-1007.	0.5	0
42	AB0369â€¦EVALUATION OF BASELINE POSITRON EMISSION TOMOGRAPHY IN THE DIAGNOSIS AND ASSESSMENT OF GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases, 2021, 80, 1210.2-1211.	0.5	0
43	CTLA-4 A49G Polymorphism and Autoimmune Blood Diseases.. Blood, 2006, 108, 3885-3885.	0.6	0
44	AB0485â€¦INVESTIGATION OF PERMANENT ORGAN DAMAGE IN GIANT CELL ARTERITIS: DISEASE FLARES ARE ASSOCIATED WITH INCREASED DAMAGE SCORES. Annals of the Rheumatic Diseases, 2020, 79, 1540.2-1540.	0.5	0
45	AB0486â€¦ANALYSIS OF 89 PATIENTS WITH GIANT CELL ARTERITIS FROM TURKEY: PET-CT AS AN EMERGING METHOD FOR DIAGNOSIS AND HIGH FLARE RATE WITH STANDARD CARE. Annals of the Rheumatic Diseases, 2020, 79, 1540.1-1541.	0.5	0
46	SAT0261â€¦FEATURES AND RISK FACTORS OF SERIOUS INFECTIONS IN ANCA ASSOCIATED VASCULITIS: LONG TERM FOLLOW UP OF 186 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1073.1-1073.	0.5	0
47	THU0369â€¦EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY. Annals of the Rheumatic Diseases, 2020, 79, 416.1-417.	0.5	0
48	SAT0346â€¦THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE ASSESSED BY ACTIVITY SCORES. Annals of the Rheumatic Diseases, 2020, 79, 1119.2-1119.	0.5	0
49	OPO274â€¦CLINICAL ASPECTS, LABORATORY CHARACTERISTICS AND TREATMENT RESPONSES OF AA AMYLOIDOSIS: SINGLE CENTER EXPERIENCE WITH 163 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 171.1-171.	0.5	0
50	THU0349â€¦THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 406.2-406.	0.5	0
51	AB0461â€¦ANCA-ASSOCIATED VASCULITIS: CLINICAL FEATURES, RELAPSE, ORGAN DAMAGE AND SURVIVAL IN 197 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1529.1-1529.	0.5	0
52	Cardiovascular risk in antiphospholipid syndrome: A comparison of thrombotic and obstetric disease subsets. Ulusal Romatoloji Dergisi, 2020, 12, 83-87.	0.0	0
53	Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center. Ulusal Romatoloji Dergisi, 2021, 13, 116-120.	0.0	0
54	Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy. Ulusal Romatoloji Dergisi, 2021, 13, 100-106.	0.0	0

#	ARTICLE	IF	CITATIONS
55	A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical Medicine Insights: Case Reports</i> , 2022, 15, 117954762211005.	0.3	0
56	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.5	0